Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuji Murakami

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Expert Review of Anticancer Therapy|November 30, 2019
Durvalumab for the treatment of non-small cell lung cancerShuji Murakami
Oncotargets and Therapy|February 23, 2023
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving ForwardKanako Shinada, Shuji Murakami
Expert Review of Anticancer Therapy|July 15, 2022
Clinically-meaningful improvements in therapy for unresectable NSCLCSeigo Katakura, Shuji Murakami
Expert Opinion on Drug Safety|May 3, 2020
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancerYuji Shibata, Shuji Murakami
Journal of Clinical Medicine|April 12, 2022
Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerRyota Ushio, Shuji Murakami, Haruhiro Saito
Expert Opinion on Drug Safety|March 2, 2021
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factorsYuji Shibata, Shuji Murakami, Terufumi Kato
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 24, 2007
[Tuberculosis associated with anti-TNF therapy]Mitsuhiro Takeno, Shuji Murakami, Yoshiaki Ishigatsubo
Thoracic Cancer|August 29, 2023
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature reviewChihiro Maeda, Kanako Shinada, Shuji Murakami, et al.
Organic Letters|November 25, 2024
Photocatalytic Denitrative Alkenylation of NitroalkanesAyumi Osawa, Kento Uemura, Shuji Murakami, et al.
American Journal of Clinical Oncology|September 30, 2009
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancerFumihiro Oshita, Haruhiro Saito, Shuji Murakami, et al.
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Expert Review of Anticancer Therapy|November 30, 2019
Durvalumab for the treatment of non-small cell lung cancerShuji Murakami
Oncotargets and Therapy|February 23, 2023
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving ForwardKanako Shinada, Shuji Murakami
Expert Review of Anticancer Therapy|July 15, 2022
Clinically-meaningful improvements in therapy for unresectable NSCLCSeigo Katakura, Shuji Murakami
Expert Opinion on Drug Safety|May 3, 2020
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancerYuji Shibata, Shuji Murakami
Journal of Clinical Medicine|April 12, 2022
Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerRyota Ushio, Shuji Murakami, Haruhiro Saito
Expert Opinion on Drug Safety|March 2, 2021
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factorsYuji Shibata, Shuji Murakami, Terufumi Kato
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 24, 2007
[Tuberculosis associated with anti-TNF therapy]Mitsuhiro Takeno, Shuji Murakami, Yoshiaki Ishigatsubo
Thoracic Cancer|August 29, 2023
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature reviewChihiro Maeda, Kanako Shinada, Shuji Murakami, et al.
Organic Letters|November 25, 2024
Photocatalytic Denitrative Alkenylation of NitroalkanesAyumi Osawa, Kento Uemura, Shuji Murakami, et al.
American Journal of Clinical Oncology|September 30, 2009
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancerFumihiro Oshita, Haruhiro Saito, Shuji Murakami, et al.
Pageof 12